Tuberculosis (TB) is preventable and treatable. Despite this, 1.6 million people died from the infectious disease in 2021—a majority of whom live in low- and middle-income countries.
Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD), with funding from global health agency
The endTB clinical trial, funded by global health agency Unitaid, has reached another milestone.
Maya* vividly remembers the day she received her diagnosis. As a 21-year-old college student in Astana, Kazakhstan, she’d been running persistent fevers and waking up drenched in sweat. Her mother insisted she get checked out.
Itumeleng Nkhabu, a 48-year-old widow, contracted tuberculosis (TB) in 2003. Then again in 2011. That was not the last time she got sick.
In 2018, she was diagnosed with multidrug-resistant tuberculosis (MDR-TB), a severe form of the respiratory disease.
Paris/Boston, 24 March 2023 – This World Tuberculosis (TB) Day, the endTB-Q clinical trial marks a critical milestone as the final patient enrolls in the study.
When a patient delivered her baby in the middle of her tuberculosis (TB) treatment, Gulnara Zhumakairova knew she would need to rally additional resources for the new mother, who was single and the sole caretaker of her newborn.
The endTB team welcomes the WHO Rapid Communication on updated guidance for the treatment of drug-resistant tuberculosis, which was released on 2 May 2022.1 This Rapid Communication continues a string of exciting advances in treatment for drug-resistant TB in recent years.
Hindustan Time released a new article about endTB in India.
"Dr Lorenzo Guglielmetti is a doctor and the Médecins Sans Frontières director of the international endTB project. Dr Vijay Chavan is a chest specialist at the MSF TB Clinic in Mumbai.
BOSTON/PARIS, October 18, 2021 — 750 patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-
Paris – Médecins Sans Frontières / Doctors Without Borders (MSF), together with its partners, is happy to announce that the endTB clinical trials have started in India.
Results from the endTB Observational Study were published July 24, 2020, in the American Journal of Respiratory and Critical Care Medicine.
After a first meeting in 2018, Médecins Sans Frontières, Sponsor of the endTB Clinical Trials, and its partners (PIH, IRD, HMS, ITM and Epicentre) have gathered for the second time the endTB Clinical Trial investigators and study coordinators in Paris.
Karachi / Paris – Médecins Sans Frontières / Doctors Without Borders (MSF) and Interactive Research and Development (IRD) are pleased to announce the start of the endTB clinical trial in Pakistan.
In March 2019, the endTB clinical trial celebrated a major milestone: the first participant completed participation in the trial. The patient, diagnosed with rifampin-resistant tuberculosis (RR-TB), started treatment and study participation in March 2017 in Tbilisi, Georgia.
endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris.
Limpho Taka, a 47-year old patient with HIV and multidrug-resistant TB, (MDR-TB) lives in Mpokochela, a village in the Drakenberg mountains of Lesotho. It takes him three hours on his horse to reach the Bobete clinic where he receives treatment for MDR-TB.
Médecins Sans Frontières / Doctors Without Borders (MSF) announces the closure of patient enrollment in the endTB clinical trial in Georgia.
Georgia continues to struggle with tuberculosis (TB), today’s leading infectious disease killer, and its drug-resistant forms. The homeless, unemployed, migrants, prisoners, and people who excessively consume alcohol are among the most affected.
Attending the UNION conference in Guadalajara (11-14 October)?
Don’t miss these events from endTB and partners.
Yury, 38, is celebrating a moment he thought would never arrive: he has been cured of a complicated form of Tuberculosis (TB), an infectious disease caused by mycobacteria which usually attacks the lungs.
For the first time in 50 years, two new drugs are available to patients battling the most trenchant forms of tuberculosis.
